AU2007216226B2 - Novel pyrone-indole derivatives and process for their preparation - Google Patents

Novel pyrone-indole derivatives and process for their preparation Download PDF

Info

Publication number
AU2007216226B2
AU2007216226B2 AU2007216226A AU2007216226A AU2007216226B2 AU 2007216226 B2 AU2007216226 B2 AU 2007216226B2 AU 2007216226 A AU2007216226 A AU 2007216226A AU 2007216226 A AU2007216226 A AU 2007216226A AU 2007216226 B2 AU2007216226 B2 AU 2007216226B2
Authority
AU
Australia
Prior art keywords
alkyl
aryl
ring
oxygen
sulphur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007216226A
Other languages
English (en)
Other versions
AU2007216226A2 (en
AU2007216226A1 (en
Inventor
Moshe Laudon
Tal Peleg-Shulman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurim Pharmaceuticals 1991 Ltd
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of AU2007216226A1 publication Critical patent/AU2007216226A1/en
Publication of AU2007216226A2 publication Critical patent/AU2007216226A2/en
Application granted granted Critical
Publication of AU2007216226B2 publication Critical patent/AU2007216226B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
AU2007216226A 2006-02-15 2007-02-13 Novel pyrone-indole derivatives and process for their preparation Active AU2007216226B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77332206P 2006-02-15 2006-02-15
US60/773,322 2006-02-15
PCT/IB2007/000330 WO2007093880A2 (en) 2006-02-15 2007-02-13 Novel pyrone-indole derivatives and process for their preparation

Publications (3)

Publication Number Publication Date
AU2007216226A1 AU2007216226A1 (en) 2007-08-23
AU2007216226A2 AU2007216226A2 (en) 2009-05-14
AU2007216226B2 true AU2007216226B2 (en) 2011-02-24

Family

ID=38283075

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007216226A Active AU2007216226B2 (en) 2006-02-15 2007-02-13 Novel pyrone-indole derivatives and process for their preparation

Country Status (21)

Country Link
US (3) US7635710B2 (enExample)
EP (1) EP1991541B1 (enExample)
JP (1) JP5248332B2 (enExample)
KR (1) KR101207736B1 (enExample)
CN (1) CN101374833B (enExample)
AU (1) AU2007216226B2 (enExample)
BR (1) BRPI0706992C8 (enExample)
CA (1) CA2642465C (enExample)
DK (1) DK1991541T3 (enExample)
EA (1) EA015605B1 (enExample)
ES (1) ES2428873T3 (enExample)
IL (1) IL193236A (enExample)
NO (1) NO339826B1 (enExample)
NZ (1) NZ569797A (enExample)
PL (1) PL1991541T3 (enExample)
PT (1) PT1991541E (enExample)
SI (1) SI1991541T1 (enExample)
TW (1) TWI501960B (enExample)
UA (1) UA104988C2 (enExample)
WO (1) WO2007093880A2 (enExample)
ZA (1) ZA200806799B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
CN103319467B (zh) * 2013-06-15 2015-10-14 湖南科技大学 一种4-[5-羟基-4-吡喃酮-2-基亚甲氨基]-3-巯基-1,2,4-三唑化合物及用途
US9637451B2 (en) 2014-01-14 2017-05-02 Astellas Pharma Inc. Indole compound
RU2561045C1 (ru) * 2014-07-15 2015-08-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный университет" (ФГБОУ ВПО "КубГУ") Нейропротекторное фармакологическое средство
US9567510B2 (en) 2014-09-11 2017-02-14 Halliburton Energy Services, Inc. Cyanamide-based carbon dioxide and/or hydrogen sulfide scavengers and methods of use in subterranean operations
KR102385665B1 (ko) * 2015-02-25 2022-04-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 질환을 치료하기 위한 5ht 작용제
SG11201901449XA (en) * 2016-08-23 2019-03-28 Neurim Pharmaceuticals 1991 Ltd Method for treating pruritus and/or itch
MX2020001342A (es) 2017-08-04 2020-08-31 Ovid Therapeutics Inc Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas.
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
MX2021003302A (es) 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
EP4149458A4 (en) 2020-05-11 2024-06-05 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University COMPOSITIONS OF TRYPTOPHOL DERIVATIVES AND 4-ETHYL-PHENOL DERIVATIVES, AND METHODS OF USE THEREOF
CN117377777A (zh) 2021-05-11 2024-01-09 纽瑞姆制药（1991）有限公司 诊断和治疗具有2号染色体2:107,510,000-107,540,000基因座单核苷酸多态性受试者的方法
IL321429A (en) 2023-01-13 2025-08-01 Neurim Pharmaceuticals 1991 Ltd Piromelatine for treating parasomnias associated with loss of rem sleep atonia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2222471A1 (en) * 1996-03-27 1997-10-02 Toray Industries, Inc. Ketone derivatives and medical application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA222247A (en) 1922-08-15 Hubert Rogers Reginald Pocket container for confections
IT1196849B (it) 1986-02-16 1988-11-25 Rotta Research Lab Nuovi derivati degli acidi 5 pentilammino 5 oxo pentaoico e 4 pentilammino 4 oxo butanoico ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
WO1992007829A1 (en) 1990-11-02 1992-05-14 The Upjohn Company Indole-3-methanamines useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
US5789440A (en) * 1993-11-19 1998-08-04 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
IL130169A (en) * 1999-05-27 2006-08-20 Neurim Pharma 1991 Indole derivatives, and pharmaceutical preparations, skin protection preparations, and cosmetics containing them
CA2406271A1 (en) * 2000-04-18 2001-10-25 Cytovia, Inc. Substituted 1,4-thiazepine and analogs and their use as activators of caspases
PE20060303A1 (es) 2004-06-23 2006-05-19 Wyeth Corp Metabolitos de indolilalquilamina como ligandos de 5-hidroxitriptamina-6
US7834050B2 (en) * 2006-03-29 2010-11-16 Duke University Small molecule insulin mimetics absent quinones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2222471A1 (en) * 1996-03-27 1997-10-02 Toray Industries, Inc. Ketone derivatives and medical application thereof

Also Published As

Publication number Publication date
JP5248332B2 (ja) 2013-07-31
US20120302620A1 (en) 2012-11-29
BRPI0706992A2 (pt) 2011-04-12
TW200835690A (en) 2008-09-01
EP1991541A2 (en) 2008-11-19
JP2009526831A (ja) 2009-07-23
KR101207736B1 (ko) 2012-12-03
IL193236A0 (en) 2009-02-11
EA015605B1 (ru) 2011-10-31
WO2007093880A3 (en) 2007-11-01
AU2007216226A2 (en) 2009-05-14
CA2642465A1 (en) 2007-08-23
NO339826B1 (no) 2017-02-06
WO2007093880A2 (en) 2007-08-23
TWI501960B (zh) 2015-10-01
CN101374833A (zh) 2009-02-25
BRPI0706992B1 (pt) 2021-05-04
SI1991541T1 (sl) 2014-02-28
US7635710B2 (en) 2009-12-22
US8242163B2 (en) 2012-08-14
US20080027121A1 (en) 2008-01-31
PL1991541T3 (pl) 2013-12-31
KR20080094945A (ko) 2008-10-27
NZ569797A (en) 2010-06-25
NO20083905L (no) 2008-09-12
BRPI0706992C8 (pt) 2021-05-25
IL193236A (en) 2012-08-30
US8569355B2 (en) 2013-10-29
UA104988C2 (uk) 2014-04-10
US20100048662A1 (en) 2010-02-25
EA200801580A1 (ru) 2009-02-27
CA2642465C (en) 2012-08-07
HK1126760A1 (en) 2009-09-11
AU2007216226A1 (en) 2007-08-23
ZA200806799B (en) 2009-10-28
BRPI0706992C1 (pt) 2021-05-18
CN101374833B (zh) 2012-06-27
DK1991541T3 (da) 2013-10-28
PT1991541E (pt) 2013-10-02
ES2428873T3 (es) 2013-11-12
EP1991541B1 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
AU2007216226B2 (en) Novel pyrone-indole derivatives and process for their preparation
US9101613B2 (en) Methods for treating neurological disease
TWI374141B (en) Spiro-oxindole compounds and their uses as therapeutic agents
CN110172051B (zh) IRE-1α抑制剂
MX2008016492A (es) Derivados de urea de tropano, su preparacion y su aplicacion terapeutica.
EA004704B1 (ru) Производные феноксипропиламина
EA007008B1 (ru) Триамидзамещённые индолы, бензофураны и бензотиофены в качестве ингибиторов микросомального белка, переносящего триглицериды, (мтр) и/или ингибиторов секреции аполипопротеина в (аро в)
HU219715B (hu) Kondenzált pirrol-karboxanilid-származékok
CN105732591B (zh) 取代的哌嗪化合物及其使用方法和用途
JPH09502177A (ja) ５ｈｔ１ｄレセプター拮抗薬用インドールおよびインドリン誘導体
JP2001512727A (ja) ５ｈｔ−１受容体のリガンドとしてのニ環式化合物
EA022776B1 (ru) Арилсульфонамиды для лечения заболеваний цнс
KR20140068241A (ko) 대사 질환 및 관련 장애의 치료를 위한 모노아실글리세롤 리파제 억제제
JP6943239B2 (ja) Ｋｃｎｑ２〜５チャネル活性化剤
WO2005028455A1 (ja) カルボン酸化合物およびそれらを有効成分として含有する医薬組成物
TW202214574A (zh) 經取代之(呔-1-基甲基)脲類、經取代之n-(呔-1-基甲基)醯胺類及其類似物
HK1126760B (en) Novel pyrone-indole derivatives and process for their preparation
JP2000507254A (ja) アザスピロ誘導体
JP4042566B2 (ja) ピペリジン化合物およびその医薬用途

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 08 APR 2009

FGA Letters patent sealed or granted (standard patent)